Enhancing CAR-T Design: CD3 Diversity for Improved Anti-Tumor Effects and Adaptability
In a recent study in Nature Immunology, methods to optimize CAR-T cells using CD3 diversity were explored.
Explore our highly homogeneous and active CD3δ/CD3ε, CD3γ/CD3ε products that could potentially help the development of your innovative CAR-T therapeutics.
Scientists utilized diverse T cell receptor (TCR) signaling domains (CD3δ, CD3ε, and CD3γ) to design a novel CAR-T cell, replacing the conventional ζ signaling domain. The study showed improved anti-tumor effects, prolonged survival, and adaptability to metabolic demands and signal intensities.
Reference: Velasco Cárdenas R M H, Brandl S M, Meléndez A V, et al. Harnessing CD3 diversity to optimize CAR T cells[J]. Nature Immunology, 2023: 1-15.
Explore our highly homogeneous and active CD3δ/CD3ε, CD3γ/CD3ε products that could potentially help the development of your innovative CAR-T therapeutics.
